Viscofan BioEngineering: Phase-I-trial approved for novel stem cell therapy for patients with ischemic cardiomyopathy

On July 4, 2018, Posted by , In News, By ,, , With Comments Off on Viscofan BioEngineering: Phase-I-trial approved for novel stem cell therapy for patients with ischemic cardiomyopathy

Viscofan BioEngineering, the biomedical business unit of the world market leader for collagenous sausage casings Viscofan announced today that the Spanish Agency for Medicines (AEMPS) has given green light to carry out a clinical phase-I-trial with Viscofan BioEngineering’s first product for regenerative medicine. The novel therapy consisting of stem cells…

University Hospital HD / Sumaya Biotech: New vaccine candidate against malaria successfully tested in first clinical trial

On May 2, 2018, Posted by , In News, By , , With Comments Off on University Hospital HD / Sumaya Biotech: New vaccine candidate against malaria successfully tested in first clinical trial

A novel vaccine candidate against the causative agent of malaria tropica, the most severe form of human malaria, has now been successfully tested for safety, tolerability and immunogenicity (ability to produce antibodies). Experts of the Department of Clinical Pharmacology and Pharmacoepidemiology of the University Hospital Heidelberg (directed by Prof. Dr….

Roche’s TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death of advanced squamous lung cancer

On March 21, 2018, Posted by , In News, By , , With Comments Off on Roche’s TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death of advanced squamous lung cancer

Phase III IMpower131 study showed Roche’s TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death in the initial treatment of people with a type of advanced squamous lung cancer Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpower131 study met…

GSK: New clinical data demonstrate high vaccine efficacy of Fluarix Tetra (Influenza Vaccine) in children 6-35 months of age

On March 6, 2018, Posted by , In News, By , , With Comments Off on GSK: New clinical data demonstrate high vaccine efficacy of Fluarix Tetra (Influenza Vaccine) in children 6-35 months of age

GSK today announced new data published in The Lancet Child & Adolescent Health from a Phase III clinical trial with Fluarix Tetra (inactivated quadrivalent influenza vaccine [IIV4]) which prevented influenza A and B in children six to 35 months of age. Vaccine efficacy was highest against moderate-to-severe influenza, where the…